Please login to the form below

Not currently logged in
Email:
Password:

patents

This page shows the latest patents news and features for those working in and with pharma, biotech and healthcare.

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire. The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court. ... Roche’s defence of its haemophilia drug Hemlibra against a patent infringement challenge by Shire has been

Latest news

  • Court throws out Allergan's patent deal with Native American tribe Court throws out Allergan's patent deal with Native American tribe

    Court throws out Allergan's patent deal with Native American tribe. Rules the contentious agreement can't protect its dry eye treatment Restasis. ... This led to rivals accusing Allergan of evading generic competition by transferring patents to the tribe

  • US court lifts ban on sales of Sanofi's Praluent US court lifts ban on sales of Sanofi's Praluent

    Praluent was approved in the US first, but Amgen filed a patent infringement suit after securing approval for its own PCSK9 drug Repatha (evolocumab). ... It is our longstanding position that Amgen’s asserted patent claims are invalid, and we remain

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    Indivior slumps as patent dispute rises US generic spectre. The RB spin out will appeal against the ruling. ... UK drugmaker Indivior suffered a major setback last week after a US patent ruling undermined one of its key products.

  • Innovation and the pharma patent court Innovation and the pharma patent court

    An important question for pharma and innovation is, will the UK government continue with its plans to formally ratify an international convention on patents called the Unified Patent Convention (UPC), that ... London would host the court that dealt with

  • Change at the top at Teva as Vigodman departs Change at the top at Teva as Vigodman departs

    The unexpected departure also comes at a tricky time for Teva, which has lost patent protection for the original formulation of cash cow product Copaxone (glatiramer acetate) for multiple sclerosis and

More from news
Approximately 84 fully matching, plus 1,020 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    No new classes of antibiotics have been introduced for more than 30 years and antibiotic patent applications worldwide.

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Patent settlement, non-exclusive licence. 200. Mallinckrodt/Baxter International.

  • Drug R&D

    Healthcare terms - Drug R&D.

  • Legal and regulatory affairs

    Healthcare terms - Legal and regulatory affairs.

  • The good, the bad and the ugly The good, the bad and the ugly

    It hopes these measures will help offset Lucentis’EU patent expiry in 2022.”. ... In Europe, a patent dispute over Lyrica became arguably the biggest CNS story in recent years.

More from intelligence
Approximately 2 fully matching, plus 101 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    Indians scalp cowboys in patent war. An unlikely treaty between global pharma and native Americans. ... At the same time, imaginative patent lawyers will be racking their brains to exploit new opportunities.

  • Global Corporate Divestment Study

    Expiring patents along with regulatory and reimbursement changes were significant divestment drivers.

  • Biosimilars: Getting the flock to market

    Patents were protected and intellectual property was defended. This is hardly surprising, as billions are at stake - Remicade alone earned Johnson &Johnson over $6bn a year, while Humira is responsible for ... Humira alone has more than a dozen

  • Tackling biosimilars – how to handle the threat to Pharma brands

    Representing millions in lost profits, the Patent Cliff was (and continues to be) a major challenge for Pharma brands. ... Their product, a treatment in the gastroenterology therapy area, had recently come off patent and a biosimilar was about to launch.

  • Pharma Brand Strategy 2.0

    However, with the competitive landscape driven by patent cliffs and generics, the complexity of multiple stakeholders and empowered patients, it’ s now time for pharma to up the ante on their ... to pay dividends post-patent.

More from PMHub
Approximately 1 fully matching, plus 40 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics